Who are Tranexamic acid intravenous administration's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tranexamic Acid (TXA), Tranexamic acid + Standard of Care, Tranexamic Acid Pill, Topical tranexamic acid, Tranexamic Acid (IV), IV TXA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tranexamic-acid-intravenous-administration.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Tranexamic acid intravenous administration — Competitive Intelligence Brief

Tranexamic acid intravenous administration (Tranexamic acid intravenous administration) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifibrinolytic agent. Area: Hematology / Hemostasis.

marketed Antifibrinolytic agent Plasminogen / Plasmin Hematology / Hemostasis Small molecule Live · refreshed every 30 min

Target snapshot

Tranexamic acid intravenous administration (Tranexamic acid intravenous administration) — Dr. Lutfi Kirdar Kartal Training and Research Hospital. Tranexamic acid inhibits the activation of plasminogen to plasmin, thereby reducing fibrinolysis and promoting blood clot stability.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tranexamic acid intravenous administration TARGET	Tranexamic acid intravenous administration	Dr. Lutfi Kirdar Kartal Training and Research Hospital	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid (TXA)	Tranexamic Acid (TXA)	NYU Langone Health	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic acid + Standard of Care	Tranexamic acid + Standard of Care	Pfizer	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid Pill	Tranexamic Acid Pill	Henry Ford Health System	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Topical tranexamic acid	Topical tranexamic acid	Aswan University Hospital	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid (IV)	Tranexamic Acid (IV)	Samsung Medical Center	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
IV TXA	IV TXA	Massachusetts General Hospital	marketed	Antifibrinolytic agent	Plasminogen / Plasmin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifibrinolytic agent class)

Montefiore Medical Center · 2 drugs in this class
Pfizer · 2 drugs in this class
Hamilton Health Sciences Corporation · 2 drugs in this class
Chinese Academy of Medical Sciences, Fuwai Hospital · 1 drug in this class
Henry Ford Health System · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class
NYU Langone Health · 1 drug in this class
Mount Sinai Hospital, Canada · 1 drug in this class
Dr. Lutfi Kirdar Kartal Training and Research Hospital · 1 drug in this class
Carlos A Acosta-Olivo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tranexamic acid intravenous administration — Competitive Intelligence Brief. https://druglandscape.com/ci/tranexamic-acid-intravenous-administration. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab